{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:57:18Z","timestamp":1792000638760,"version":"4.4.0"},"reference-count":22,"publisher":"Japanese Circulation Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2024,12,25]]},"DOI":"10.1253\/circj.cj-24-0501","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T22:11:10Z","timestamp":1730931070000},"page":"130-138","source":"Crossref","is-referenced-by-count":25,"title":["Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy\u3000\u2015 The HORIZON-HCM Study \u2015"],"prefix":"10.1253","volume":"89","author":[{"given":"Hiroaki","family":"Kitaoka","sequence":"first","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ieda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Keio University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mio","family":"Ebato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Showa University Fujigaoka Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kozuma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Teikyo University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morimasa","family":"Takayama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sakakibara Heart Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Tanno","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular Center, Showa University Koto Toyosu Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Komiyama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, St. Luke\u2019s International Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women\u2019s Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Ogimoto","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Uwajima City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Takaya","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Hyogo Prefectural Harima-Himeji General Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Amiya","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka General Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daigo","family":"Hiraya","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institute of Medicine, University of Tsukuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Miyagoshi","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Reedy","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila M.","family":"Hegde","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Florea","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisato","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). <i>Eur Heart J<\/i> 2023; 44: 3503\u20133626.","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: A report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. <i>Circulation<\/i> 2024; 149: e1239\u2013e1311.","DOI":"10.1161\/CIR.0000000000001250"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. <i>J Am Coll Cardiol<\/i> 2022; 79: 372\u2013389.","DOI":"10.1016\/j.jacc.2021.12.002"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kitaoka H, Tsutsui H, Kubo T, Ide T, Chikamori T, Fukuda K, et al. JCS\/JHFS 2018 guideline on the diagnosis and treatment of cardiomyopathies. <i>Circ J<\/i> 2021; 85: 1590\u20131689.","DOI":"10.1253\/circj.CJ-20-0910"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: Clinical update. <i>JACC Heart Fail<\/i> 2018; 6: 364\u2013375.","DOI":"10.1016\/j.jchf.2018.02.010"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Zaiser E, Sehnert AJ, Duenas A, Saberi S, Brookes E, Reaney M. Patient experiences with hypertrophic cardiomyopathy: A conceptual model of symptoms and impacts on quality of life. <i>J Patient Rep Outcomes<\/i> 2020; 4: 102.","DOI":"10.1186\/s41687-020-00269-8"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Marian AJ, Braunwald E. Hypertrophic cardiomyopathy. <i>Circ Res<\/i> 2017; 121: 749\u2013770.","DOI":"10.1161\/CIRCRESAHA.117.311059"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hada Y, Sakamoto T, Amano K, Yamaguchi T, Takenaka K, Takahashi H, et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. <i>Am J Cardiol<\/i> 1987; 59: 183\u2013184.","DOI":"10.1016\/S0002-9149(87)80107-8"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2015; 65: 1249\u20131254.","DOI":"10.1016\/j.jacc.2015.01.019"},{"key":"10","unstructured":"10. CAMZYOS (mavacamten). US prescribing information. Bristol-Myers Squibb Company, 2024. https:\/\/packageinserts.bms.com\/pi\/pi_camzyos.pdf (accessed July 5, 2024)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Anderson RL, Trivedi DV, Sarkar SS, Henze M, Ma W, Gong H, et al. Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. <i>Proc Natl Acad Sci USA<\/i> 2018; 115: E8143\u2013E8152.","DOI":"10.1073\/pnas.1809540115"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet<\/i> 2020; 396: 759\u2013769.","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: Results of the VALOR-HCM trial. <i>J Am Coll Cardiol<\/i> 2022; 80: 95\u2013108.","DOI":"10.1016\/j.jacc.2022.04.048"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tian Z, Li L, Li X, Wang J, Zhang Q, Li Z, et al. Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: The EXPLORER-CN randomized clinical trial. <i>JAMA Cardiol<\/i> 2023; 8: 957\u2013965.","DOI":"10.1001\/jamacardio.2023.3030"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Walpole SC, Prieto-Merino D, Edwards P, Cleland J, Stevens G, Roberts I. The weight of nations: An estimation of adult human biomass. <i>BMC Public Health<\/i> 2012; 12: 439.","DOI":"10.1186\/1471-2458-12-439"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. <i>Clin Pharmacol Ther<\/i> 2011; 90: 328\u2013332.","DOI":"10.1038\/clpt.2011.132"},{"key":"17","unstructured":"17. Dean L. Carisoprodol therapy and <i>CYP2C19<\/i> genotype. 2017. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK425390\/ (accessed September 20, 2024)."},{"key":"18","unstructured":"18. Okutsu H, Back H, Seroogy J, Florea V, Merali S. Ethno-bridging of mavacamten pharmacokinetics in healthy Japanese participants, and the impact of CYP2C19 phenotype. <i>In:<\/i> 88th Annual Scientific Meeting of the Japanese Circulation Society. Kobe, Japan; March 8\u201310, 2024."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Chang P, Perera V, Salinger DH, Merali S, Thanneer N, Back H, et al. Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration. <i>CPT Pharmacometrics Syst Pharmacol<\/i> 2024; 13: 1462\u20131475.","DOI":"10.1002\/psp4.13197"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Spertus JA, Fine JT, Elliott P, Ho CY, Olivotto I, Saberi S, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): Health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet<\/i> 2021; 397: 2467\u20132475.","DOI":"10.1016\/S0140-6736(21)00763-7"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hegde SM, Lester SJ, Solomon SD, Michels M, Elliott PM, Nagueh SF, et al. Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2021; 78: 2518\u20132532.","DOI":"10.1016\/j.jacc.2021.09.1381"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>J Am Soc Echocardiogr<\/i> 2015; 28: 1\u201339.e14.","DOI":"10.1016\/j.echo.2014.10.003"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/89\/1\/89_CJ-24-0501\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T03:18:22Z","timestamp":1735355902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/89\/1\/89_CJ-24-0501\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,25]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-24-0501","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,25]]},"article-number":"CJ-24-0501"}}